Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | RARA | P10276 | 3/20 | 0.40 |
| ▸ | RARB | P10826 | 3/20 | 0.40 |
| ▸ | RARG | P13631 | 3/20 | 0.40 |
| ▸ | ESR1 | P03372 | 3/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MIF | P14174 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11367750 | 0.85 | ESR2 (0.44) | KDM4EALDH1A1OPRD1KCNH2RARA | |
| SCHEMBL12082011 | 0.84 | RARA (0.46) | OPRD1KCNH2RARARARBRARG | |
| SCHEMBL13566250 | 0.83 | ESR2 (0.44) | KDM4EALDH1A1OPRD1KCNH2RARA | |
| SCHEMBL3023515 | 0.83 | RARA (0.38) | KDM4ERARARARBRARGPPARG | |
| SCHEMBL3027431 | 0.83 | NPC1 (0.40) | KDM4ERARARARBRARGRAB9A | |
| SCHEMBL12017334 | 0.82 | OPRD1 (0.43) | KDM4EALDH1A1OPRD1KCNH2ESR1 | |
| SCHEMBL3023824 | 0.80 | KDM4E (0.37) | KDM4EALDH1A1OPRD1KCNH2RARA | |
| SCHEMBL14666717 | 0.80 | RARA (0.38) | ALDH1A1RARARARBRARGMEN1 | |
| SCHEMBL13214224 | 0.80 | RARA (0.39) | ALDH1A1RARARARBRARGPPARG | |
| SCHEMBL11361462 | 0.80 | RARA (0.46) | KDM4EALDH1A1OPRD1KCNH2RARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2179994-B1 | FUSED BICYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-06-26 | — | — | EP | disclosed |
| US-8410166-B2 | Fused bicyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-04-02 | — | — | US | disclosed |
| US-8410166-B2 | Fused bicyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-04-02 | — | — | US | disclosed |
| US-8410166-B2 | Fused bicyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-04-02 | — | — | US | disclosed |
| US-20130029979-A1 | FUSED BICYCLIC COMPOUND | TAKAHASHI YOICHI (JP) | 2013-01-31 | — | — | US | disclosed |
| US-20130029979-A1 | FUSED BICYCLIC COMPOUND | TAKAHASHI YOICHI (JP) | 2013-01-31 | — | — | US | disclosed |
| US-8258131-B2 | Fused bicyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-09-04 | — | — | US | disclosed |
| US-8258131-B2 | Fused bicyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-09-04 | — | — | US | disclosed |
| US-8258131-B2 | Fused bicyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-09-04 | — | — | US | disclosed |
| US-20100204218-A1 | FUSED BICYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-08-12 | — | — | US | disclosed |
| US-20100204218-A1 | FUSED BICYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-08-12 | — | — | US | disclosed |
| US-20100204218-A1 | FUSED BICYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-08-12 | — | — | US | disclosed |
| EP-2179994-A1 | FUSED BICYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029979-A1 | FUSED BICYCLIC COMPOUND | NR3C2, NR3C1, MC2R | KDM4E 1296/4885ALDH1A1 4156/4885OPRD1 268/4885 |
| US-20100204218-A1 | FUSED BICYCLIC COMPOUND | NR3C2, NR3C1, MC2R | KDM4E 1217/4885ALDH1A1 4064/4885OPRD1 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.